Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 11 of the 13 references it cites were found in a registry or an index.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Open access
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, Lesley, Jenkins, Valerie, Kilkerr, Justine, Langridge, Carolyn, Monson, Kathryn, Jakobsen, Erik Hugger, Nielsen, Mette Holck, Linnet, Soeren, Knoop, Ann, Pivot, Xavier, Bonnefoi, Herve, Mousseau, Mireille, Zelek, Laurent, Bourgeois, Hugues, Lefeuvre, Claudia Plesse, Bachelot, Thomas, Petit, Thierry, Brain, Etienne, Levy, Christelle, Gligorov, Joseph, Augustin, Doris, Graf, Heiko, Heinrich, Georg, Kroening, Hendrik, Kuemmel, Sherko, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-Won, Schmidt, Marcus, Perlova-Griff, Lidia, Wolf, Christopher, Colleoni, Marco, Ballestrero, Alberto, Bernardo, Antonio, Ribecco, Angela Stefania, Gianni, Luca, Curigliano, Giuseppe, Brewczynska, Elżbieta, Jassem, Jacek, Shirinkin, Vadim, Manikhas, Alexey, Dvornichenko, Victoria, Lichinitser, Mikhail, Semiglazov, Vladimir, Mukhametshina, Guzel, Bulavina, Irina, Arranz, Enrique Espinosa, Ocon, Francisco Carabantes, Vivanco, Guillermo López, Bofill, Javier Salvador, Quintela, Ignacio Porras, Muñoz, Alfonso Sanchez, Pérez, Yolanda Fernández, Espinosa, Javier Cassinello, Alvarez, José Valero, del Prado, Rodrigo Lastra, De Merino, LuisLa Cruz, García, José Manuel Pérez, Frances, Santos Enrech, Edlund, Per, Norberg, Bengt, Wennstig, Anna-Karin, Lind, Pehr, Hauser, Nik, Tausch, Christoph, Camci, Celalettin, Arpaci, Fikret, Abali, Huseyin, Uslu, Ruchan, Tahir, Saad, Wheatley, Duncan, Chan, Stephen, Barrett-Lee, Peter, McAdam, Karen, Simcock, Richard, Burcombe, Russell, El-Maraghi, Robert, Califaretti, Nadia, Spadafora, Silvana, Sehdev, Sandeep, Sami, Amer, Verma, Sunil · 2014 · Annals of Oncology

Abstract

Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.) trastuzumab, delivered via single-use injection device (SID), over the intravenous (i.v.) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here, we report patient preference, healthcare professional satisfaction, and safety data pooled from Cohort 1 and also Cohort 2, where s.c. trastuzumab was delivered via hand-held syringe.Patients and methods Patients were randomized to receive four adjuvant cycles of 600 mg fixed-dose s.c. trastuzumab followed by four cycles of standard i.v. trastuzumab, or vice versa. The primary endpoint was overall preference proportions for s.c. or i.v., assessed by patient interviews in the evaluable ITT population.Results A total of 245 patients were randomized to receive s.c. followed by i.v. and 243 received i.v. followed by s.c. (evaluable ITT populations: 235 and 232 patients, respectively). s.c. was preferred by 415/467 [88.9%; 95% confidence interval (CI) 85.7-91.6; P < 0.0001; two-sided test against null hypothesis of 65% s.c. preference]; 45/467 preferred i.v. (9.6%; 95% CI 7-13); 7/467 indicated no preference (1.5%; 95% CI 1-3). Clinician-reported adverse events occurred in 292/479 (61.0%) and 245/478 (51.3%) patients during the pooled s.c. and i.v. periods, respectively (P < 0.05; 2 × 2 χ(2)); 16 patients (3.3%) in each period experienced grade 3 events; none were grade 4/5.Conclusions PrefHer revealed compelling and consistent patient preferences for s.c. over i.v. trastuzumab, regardless of SID or hand-held syringe delivery. s.c. was well tolerated and safety was consistent with previous reports, including the HannaH study (NCT00950300). No new safety signals were identified compared with the known i.v. profile in EBC. PrefHer and HannaH confirm that s.c. trastuzumab is a validated and preferred option over i.v. for improving patients' care in HER2-positive breast cancer.Clinicaltrialsgov registration number NCT01401166.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdu364

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 13 references

Research works printed but not linked: 6

  1. National Comprehensive Cancer Network, 2014, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
  2. De Cock, 2013, Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study., Eur J Cancer, 49, S432
  3. ICH Harmonised Tripartite Guideline, 1995, Clinical safety data management: definitions and standards for expedited reporting E2A
  4. Fallowfield, 2013, Reasons for patients’ preferences for subcutaneous or intravenous trastuzumab in the PrefHer study, Eur J Cancer, 49, S385
  5. Gligorov J, Curigliano G, Müller V et al. Assessment of adverse events in patients switching between trastuzumab administration routes (subcutaneous to intravenous and intravenous to subcutaneous) in the PrefHer study. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 229.
  6. De Cock E, Pan I, Sandoval M et al. Healthcare professionals’ perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 42.

Cited by

See all 177

Metadata

Authors
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, L., Jenkins, V., Kilkerr, J., Langridge, C., Monson, K., Jakobsen, E. H., Nielsen, M. H., Linnet, S., Knoop, A., Pivot, X., Bonnefoi, H., Mousseau, M., Zelek, L., Bourgeois, H., Lefeuvre, C. P., Bachelot, T., Petit, T., Brain, E., Levy, C., Gligorov, J., Augustin, D., Graf, H., Heinrich, G., Kroening, H., Kuemmel, S., Müller, V., Overkamp, F., Park-Simon, T.-W., Schmidt, M., Perlova-Griff, L., Wolf, C., Colleoni, M., Ballestrero, A., Bernardo, A., Ribecco, A. S., Gianni, L., Curigliano, G., Brewczynska, E., Jassem, J., Shirinkin, V., Manikhas, A., Dvornichenko, V., Lichinitser, M., Semiglazov, V., Mukhametshina, G., Bulavina, I., Arranz, E. E., Ocon, F. C., Vivanco, G. L., Bofill, J. S., Quintela, I. P., Muñoz, A. S., Pérez, Y. F., Espinosa, J. C., Alvarez, J. V., del Prado, R. L., De Merino, L. C., García, J. M. P., Frances, S. E., Edlund, P., Norberg, B., Wennstig, A.-K., Lind, P., Hauser, N., Tausch, C., Camci, C., Arpaci, F., Abali, H., Uslu, R., Tahir, S., Wheatley, D., Chan, S., Barrett-Lee, P., McAdam, K., Simcock, R., Burcombe, R., El-Maraghi, R., Califaretti, N., Spadafora, S., Sehdev, S., Sami, A., & Verma, S.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • European Institute of Oncology (IT)
  • Sunnybrook Health Science Centre (CA)
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2014-10
Volume
25
Issue
10
Pages
1979-1987
ISSN
0923-7534 (ISSN-L)
OpenAlex
W1549851394
Cited by
177
References
13
Citations by year
2026: 13 · 2025: 23 · 2024: 14 · 2023: 11 · 2022: 9 · 2021: 21 · 2020: 19 · 2019: 12 · 2018: 9 · 2017: 16 · 2016: 13 · 2015: 14 · 2014: 2
FWCI
7.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • reroDoc Digital Library (submittedVersion)
  • Sussex Research Online (University of Sussex) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • HighWire Press Open Archive (submittedVersion)
Funders
F. Hoffmann-La Roche Ltd
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
subcutaneous trastuzumab, HER2-positive early breast cancer, adjuvant therapy, patient preferences, healthcare professional satisfaction, adverse events, drug delivery routes, patient-reported outcomes, safety and tolerability, patient-reported quality of life
MeSH terms
Trastuzumab, Adult, Aged, Breast Neoplasms, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Cohort Studies, Treatment Outcome, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. https://app.cochat.ai/papers/10.1093/annonc/mdu364
The paper
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, L., Jenkins, V., Kilkerr, J., Langridge, C., Monson, K., Jakobsen, E. H., Nielsen, M. H., Linnet, S., Knoop, A., . . . Verma, S. (2014). Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of Oncology. https://doi.org/10.1093/annonc/mdu364

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.